Oral mucositis: time for more studies.
Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic effects, local inflammatory responses, and alterations in oral microflora. There are currently no approved agents for the prevention or treatment of OM. In this review we briefly describe current knowledge of the pathophysiology, clinical presentation, and management of OM. We then discuss investigational agents being studied in OM with a particular focus on local antimicrobial agents, hemopoietic growth factors, and cytokines. Measures to reduce the incidence of OM and/or alleviate its clinical sequelae should be incorporated into all chemotherapy or radiotherapy studies.
Alvarado
Yesid
Y
Department of Leukemia, M.D. Anderson Cancer Center, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
Bellm
Lisa A
LA
Giles
Francis J
FJ
D000970:Antineoplastic Agents / Q000009:adverse effects; D019468:Disease Management; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D017053:Infection Control; D009061:Mouth Mucosa / Q000473:pathology*; D013280:Stomatitis / Q000209:etiology / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents